Key result
The sGC activator BAY 58-2667 prevented oxidation-induced sGC ubiquitination and stabilized both alpha and beta subunits in isolated blood vessels.
The sGC activator BAY 58-2667 prevents oxidation-induced ubiquitination and proteasomal degradation of sGC, revealing a novel receptor-stabilizing mechanism for this class of vasodilators.
No takes yet. Share an insight, caveat, or question.
Novel sGC stabilization mechanism under oxidation; hypothesis-generating for vasodilator therapy in oxidative vascular disease.
Meurer et al. (2009) studied Vascular diseases. BAY 58-2667 was evaluated on sGC ubiquitination and proteasomal degradation. The sGC activator BAY 58-2667 prevented oxidation-induced sGC ubiquitination and stabilized both alpha and beta subunits in isolated blood vessels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: